Abstract
In
the
past
decade,
cancer
immunotherapy
has
revolutionized
field
of
oncology.
Major
approaches
such
as
immune
checkpoint
inhibitors,
vaccines,
adoptive
cell
therapy,
cytokines,
and
immunomodulators
have
shown
great
promise
in
preclinical
clinical
settings.
Among
them,
immunomodulatory
agents
including
vaccines
are
particularly
appealing;
however,
they
face
limitations,
notably
absence
efficient
precise
targeted
delivery
immune‐modulatory
to
specific
cells
potential
for
off‐target
toxicity.
Nanomaterials
can
play
a
pivotal
role
addressing
targeting
other
challenges
immunotherapy.
Dendritic
mesoporous
silica
nanoparticles
(DMSNs)
enhance
efficacy
by
enhancing
effective
loading
modulatory
owing
their
tunable
pore
sizes.
this
work,
an
emulsion‐based
method
is
optimized
customize
size
DMSNs
loaded
with
ovalbumin
(OVA)
cytosine‐phosphate‐guanine
(CpG)
oligodeoxynucleotides
(CpG‐OVA‐DMSNs).
The
immunotherapeutic
effect
achieved
through
controlled
chemical
release
OVA
CpG
antigen‐presenting
(APCs).
results
demonstrated
that
CpG‐OVA‐DMSNs
efficiently
activated
response
APCs
reduced
tumor
growth
murine
B16‐OVA
model.
Abstract
Cancer
nanovaccines
represent
a
promising
frontier
in
cancer
immunotherapy,
utilizing
nanotechnology
to
augment
traditional
vaccine
efficacy.
This
review
comprehensively
examines
the
current
state‐of‐the‐art
nanovaccine
development,
elucidating
innovative
strategies
and
technologies
employed
their
design.
It
explores
both
preclinical
clinical
advancements,
emphasizing
key
studies
demonstrating
potential
elicit
robust
anti‐tumor
immune
responses.
The
study
encompasses
various
facets,
including
integrating
biomaterial‐based
nanocarriers
for
antigen
delivery,
adjuvant
selection,
impact
of
nanoscale
properties
on
performance.
Detailed
insights
into
complex
interplay
between
tumor
microenvironment
responses
are
provided,
highlighting
challenges
opportunities
optimizing
therapeutic
outcomes.
Additionally,
presents
thorough
analysis
ongoing
trials,
presenting
snapshot
landscape.
By
curating
latest
scientific
findings
developments,
this
aims
serve
as
comprehensive
resource
researchers
clinicians
engaged
advancing
immunotherapy.
Integrating
design
holds
immense
promise
revolutionizing
treatment
paradigms,
provides
timely
update
evolving
landscape
nanovaccines.
Nano-Micro Letters,
Год журнала:
2025,
Номер
17(1)
Опубликована: Фев. 24, 2025
Abstract
Sonodynamic
therapy
(SDT)
as
an
emerging
modality
for
malignant
tumors
mainly
involves
in
sonosensitizers
and
low-intensity
ultrasound
(US),
which
can
safely
penetrate
the
tissue
without
significant
attenuation.
SDT
not
only
has
advantages
including
high
precision,
non-invasiveness,
minimal
side
effects,
but
also
overcomes
limitation
of
low
penetration
light
to
deep
tumors.
The
cytotoxic
reactive
oxygen
species
be
produced
by
utilization
combined
with
US
kill
tumor
cells.
However,
underlying
mechanism
been
elucidated,
its
unsatisfactory
efficiency
retards
further
clinical
application.
Herein,
we
shed
on
main
mechanisms
types
sonosensitizers,
organic
inorganic
sonosensitizers.
Due
development
nanotechnology,
many
novel
nanoplatforms
are
utilized
this
arisen
field
solve
barriers
enable
continuous
innovation.
This
review
highlights
potential
nanosonosensitizers
focus
enhanced
based
monotherapy
or
synergistic
that
difficult
reach
traditional
treatment,
especially
orthotopic
cancers.
Nano-Micro Letters,
Год журнала:
2023,
Номер
16(1)
Опубликована: Ноя. 20, 2023
Massive
efforts
have
been
concentrated
on
the
advance
of
eminent
near-infrared
(NIR)
photothermal
materials
(PTMs)
in
NIR-II
window
(1000-1700
nm),
especially
organic
PTMs
because
their
intrinsic
biological
safety
compared
with
inorganic
PTMs.
However,
so
far,
only
a
few
NIR-II-responsive
was
explored,
and
conversion
efficiencies
(PCEs)
still
remain
relatively
low.
Herein,
donor-acceptor
conjugated
diradical
polymers
open-shell
characteristics
are
explored
for
synergistically
immunotherapy
metastatic
tumors
window.
By
employing
side-chain
regulation,
polymer
TTB-2
obvious
absorption
developed,
its
nanoparticles
realize
record-breaking
PCE
87.7%
upon
light
illustration.
In
vitro
vivo
experiments
demonstrate
that
show
good
tumor
photoablation
navigation
photoacoustic
imaging
window,
without
any
side-effect.
Moreover,
by
combining
PD-1
antibody,
pulmonary
metastasis
breast
cancer
is
high-effectively
prevented
efficient
photo-immunity
effect.
Thus,
this
study
explores
superior
theranostics
offering
new
horizon
developing
radical-characteristic
materials.
Chemical Society Reviews,
Год журнала:
2024,
Номер
53(15), С. 7657 - 7680
Опубликована: Янв. 1, 2024
Nanomaterials
exhibit
significant
potential
for
stimulating
immune
responses,
offering
both
local
and
systemic
modulation
across
a
variety
of
diseases.
The
lymphoid
organs,
such
as
the
spleen
lymph
nodes,
are
home
to
various
cells,
including
monocytes
dendritic
which
contribute
progression
prevention/treatment
Consequently,
many
nanomaterial
formulations
being
rationally
designed
target
these
organs
engage
with
specific
cell
types,
thereby
inducing
therapeutic
protective
effects.
In
this
review,
we
explore
crucial
cellular
interactions
processes
involved
in
regulation
highlight
innovative
nano-based
immunomodulatory
approaches.
We
outline
essential
considerations
design
an
emphasis
on
their
impact
biological
interactions,
targeting
capabilities,
treatment
efficacy.
Through
selected
examples,
illustrate
strategic
therapeutically
active
nanomaterials
subsequent
immunomodulation
infection
resistance,
inflammation
suppression,
self-antigen
tolerance,
cancer
immunotherapy.
Additionally,
address
current
challenges,
discuss
emerging
topics,
share
our
outlook
future
developments
field.
Journal of Nanobiotechnology,
Год журнала:
2024,
Номер
22(1)
Опубликована: Июнь 28, 2024
Abstract
Lipid
nanoparticles
(LNPs)
have
proven
themselves
as
transformative
actors
in
chimeric
antigen
receptor
(CAR)
T
cell
therapy,
surpassing
traditional
methods
and
addressing
challenges
like
immunogenicity,
reduced
toxicity,
improved
safety.
Promising
preclinical
results
signal
a
shift
toward
safer
more
effective
CAR
treatments.
Ongoing
research
aims
to
validate
these
findings
clinical
trials,
marking
new
era
guided
by
LNPs
utility
therapy.
Herein,
we
explore
the
preference
for
over
methods,
highlighting
versatility
of
their
delivery
nucleic
acids.
Additionally,
address
key
considerations,
heralding
Graphical
